Zhen Gao

Zhen Gao

Auto-generated profile, based on publicly available information

Zhen Gao

Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2023 in The Lancet Regional Health - Western Pacific
Verified
Journal Article
Open access
ZGZhen Gao
Zhen Gao
SHShujie Huang
Shujie Huang
SWSichao Wang
Sichao Wang
DTDezhao Tang
Dezhao Tang
WXWei Xu
Wei Xu
GQGuibin Qiao
Guibin Qiao
The treatment of esophageal cancer has entered a new phase with the development of immunotherapy. The current investigation purpose is to investigate and contrast the efficacy and safety of immunotherapy, immunochemotherapy, chemotherapy, and targeted therapy as first-line treatment for individuals suffering from advanced and metastatic esophageal cancer. Within the framework of this systematic review and network meta-analysis, clinical trials published or reported in English up until 01 May, 2022, were retrieved from Embase, PubMed, Cochrane Central Register of Controlled Trials, the ClinicalTrials.gov databases, ESMO, and ASCO. The analysis incorporated randomized controlled trials (RCTs) from phase 2 to 3 that evaluated a minimum of two first-line therapeutic regimens for metastatic esophageal cancer were included in the analysis. The primary outcomes were overall survival (OS) and progression-free survival (PFS). Secondary clinical outcomes included the incidence of objective response rate (ORR), and adverse events (AEs) of any grade and ≥3 grade. Relative summary data were extracted from included studies by GZ, HS, WS, and TD. For clear statistical analysis, chemotherapy was divided into two categories of fluorouracil-based chemotherapy (FbCT) and fluorouracil-free chemotherapy (FfCT). Bayesian frequentist approach was employed to conduct the network meta-analysis. The indirect intercomparison between regimens was presented with league tables (HRs and 95% CI for OS and PFS, ORs and 95% CI for ORR and AEs). A greater surface value under the cumulative ranking (SUCRA) indicates a higher potential ranking for the corresponding treatment. A further calculation of relative results about esophageal squamous cell cancer was performed in the subgroup analysis. The current protocol for the systematic review has been properly registered on PROSPERO (registration number: CRD42021241145). The final analysis comprised 17 trials that involved 9128 patients and 19 distinct treatment regimens. Within the scope of investigated immunotherapy (IO) combinations, toripalimab + FfCT (tori + FfCT) demonstrated the best OS advantages (tori + FfCT vs. FbCT, HR 0.57, 95% CI 0.38–0.85; tori + FfCT vs. FfCT, HR 0.58, 95% CI 0.43–0.78). In terms of PFS, camrelizumab + FfCT (cam + FfCT) demonstrated the best PFS advantages (FbCT vs. cam + FfCT, HR 1.79, 95% CI 1.22–2.63; FfCT vs. cam + FfCT, HR 1.79, 95% CI 1.47–2.17). Nivolumab + FbCT (nivo + FbCT vs. FfCT, OR 3.29, 95% CI 1.43–7.56) showed the best objective responses. Compared to the conventional chemotherapy regimen, the toxicity was observed to be the slightest for the tori + FfCT (FbCT vs. tori + FfCT, OR 3.07, 95% CI 1.22–7.7) and sintilimab + FfCT (FbCT vs. sin + FfCT, OR 2.93, 95% CI 1.16–7.37). The results in this study were evaluated as having a low heterogeneity since the I2 value was ≤25% in all analyses. Compared to foreign IO combinations, sin + FfCT, tori + FfCT, cam + FfCT, and tisle + FbCT are superior first-line treatment options for patients with advanced and metastatic esophageal cancer. Although foreign IO combinations, such as pembro + FbCT and nivo + FbCT obtained better objective response rates than other IO combinations, the addition of chemotherapy to IO worsens the safety profiles. Our findings could provide complementary evidence for current guideline recommendations. This work was supported by a grant from the Science and Technology Program of Guangzhou, China (202206010103); and 10.13039/501100003453 Natural Science Foundation of Guangdong Province (2022A1515012469).

15 February 2026 in Journal of the National Cancer Center
Verified
Journal Article
Open access
SWSi-Chao Wang
Si-Chao Wang
ZYZheng-Hao Ye
Zheng-Hao Ye
HZHan Zhou
Han Zhou
ZZZe-Rui Zhao
Ze-Rui Zhao
YZYu-Heng Zhou
Yu-Heng Zhou
FKFeng-Ming Kong
Feng-Ming Kong

14 October 2023 in The Lancet Regional Health - Western Pacific
Verified
Journal Article
Open access
ZGZhen Gao
Zhen Gao
SHShujie Huang
Shujie Huang
SWSichao Wang
Sichao Wang
DTDezhao Tang
Dezhao Tang
WXWei Xu
Wei Xu
GQGuibin Qiao
Guibin Qiao